Lakefront Biotherapeutics (LKFT) Operating Expenses (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Operating Expenses of -$36.3 million for Q1 2026, up 81.11% year-over-year from -$20.0 million in Q1 2025, and up 71.0% quarter-over-quarter from -$125.1 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Operating Expenses (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Operating Expenses for 12 consecutive years, with -$36.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 81.11% year-over-year to -$36.3 million; the TTM figure through Mar 2026 stood at -$355.7 million (up 6.94% YoY), while the FY2025 annual figure was -$534.8 million, down 49.16% from the prior year.
- Operating Expenses advanced to -$36.3 million in Q1 2026 per LKFT's latest filing, from -$125.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $619.9 million in Q4 2022 and bottomed at -$204.6 million in Q4 2023.
- Historically, Operating Expenses has averaged -$43.4 million across 5 years, with a median of -$77.8 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 95.77% — and 2025, when it tumbled 1345.7%.
- Lakefront Biotherapeutics' Operating Expenses stood at $619.9 million in 2022, then tumbled by 133.01% to -$204.6 million in 2023, then soared by 95.77% to -$8.7 million in 2024, then sank by 1345.7% to -$125.1 million in 2025, then surged by 71.0% to -$36.3 million in 2026.
- Business Quant data shows LKFT's Operating Expenses at -$36.3 million in Q1 2026, -$125.1 million in Q4 2025, and -$86.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | -36.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.29 Mn |
| Dec 31, 2025 | -125.13 Mn |
| Sep 30, 2025 | -86.39 Mn |
| Jun 30, 2025 | -107.88 Mn |
| Mar 31, 2025 | -192.18 Mn |
| Dec 31, 2024 | -8.66 Mn |
| Sep 30, 2024 | -102.13 Mn |
| Jun 30, 2024 | -79.26 Mn |
| Mar 31, 2024 | -77.78 Mn |
| Dec 31, 2023 | -204.64 Mn |
| Sep 30, 2023 | -63.68 Mn |
| Jun 30, 2023 | -61.20 Mn |
| Mar 31, 2023 | -56.35 Mn |
| Dec 31, 2022 | 619.94 Mn |
| Mar 31, 2022 | -69.97 Mn |
| Jun 30, 2021 | -240.64 Mn |
| Mar 31, 2021 | -54.23 Mn |
| Dec 31, 2020 | 1.37 Bn |
| Sep 30, 2020 | -104.54 Mn |
| Jun 30, 2020 | -222.30 Mn |